One of the major pharma companies looking to produce a vaccine for COVID-19 is looking to manufacture in Maryland.

AstraZeneca this week said it signed an agreement with Catalent to make drug substance for the vaccine at the latter company’s commercial gene therapy facility near BWI airport. The facility will be prepared so multiple production trains can run in parallel to produce the drug substance in the third quarter of 2021.

The 200,000-square-foot facility, which opened last year, was acquired by New Jersey-based Catalent when it bought Baltimore-born Paragon Bioservices in a $1.2 billion deal. AstraZeneca is also working with a Catalent facility in Anagni, Italy, that will preform vial filling and packaging for the vaccine.

READ FULL ARTICLE HERE